Summary
Global Markets Direct’s, ‘Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2016’, provides an overview of the Gastrointestinal Stromal Tumor (GIST) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)
- The report reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Gastrointestinal Stromal Tumor (GIST) therapeutics and enlists all their major and minor projects
- The report assesses Gastrointestinal Stromal Tumor (GIST) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AB Science SA
Advenchen Laboratories, LLC
Ariad Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Boston Biomedical, Inc.
Calithera Biosciences, Inc.
Chipscreen Biosciences Ltd
Deciphera Pharmaceuticals, LLC
F. Hoffmann-La Roche Ltd.
Horizon Pharma Plc
Immunicum AB
Jiangsu Hengrui Medicine Co., Ltd.
Kolltan Pharmaceuticals, Inc.
Natco Pharma Limited
Nerviano Medical Sciences S.r.l.
Novartis AG
Omeros Corporation
Plexxikon Inc.
TG Therapeutics, Inc.
Threshold Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Gastrointestinal Stromal Tumor (GIST) Overview 10
Therapeutics Development 11
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview 11
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis 12
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies 13
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes 15
Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies 19
Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes 21
Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 22
AB Science SA 22
Advenchen Laboratories, LLC 23
Ariad Pharmaceuticals, Inc. 24
Arog Pharmaceuticals, Inc. 25
Array BioPharma Inc. 26
Astex Pharmaceuticals, Inc. 27
Blueprint Medicines Corporation 28
Boston Biomedical, Inc. 29
Calithera Biosciences, Inc. 30
Chipscreen Biosciences Ltd 31
Deciphera Pharmaceuticals, LLC 32
F. Hoffmann-La Roche Ltd. 33
Horizon Pharma Plc 34
Immunicum AB 35
Jiangsu Hengrui Medicine Co., Ltd. 36
Kolltan Pharmaceuticals, Inc. 37
Natco Pharma Limited 38
Nerviano Medical Sciences S.r.l. 39
Novartis AG 40
Omeros Corporation 41
Plexxikon Inc. 42
TG Therapeutics, Inc. 43
Threshold Pharmaceuticals, Inc. 44
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Combination Products 46
Assessment by Target 47
Assessment by Mechanism of Action 50
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
alpelisib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
apatinib - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
BB-503 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
binimetinib - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BLU-285 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
buparlisib hydrochloride - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
CB-839 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
CHMFLKIT-110 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
crenolanib besylate - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
CS-2164 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
DCC-2618 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
evofosfamide - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
infigratinib - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
interferon gamma-1b - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Intuvax - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
KTN-0158 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
masitinib - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
nilotinib - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
NMSP-088 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
NRCAN-019 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
onalespib - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
pexidartinib - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
PLX-9486 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
ponatinib hydrochloride - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
SF-1126 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
SHR-1020 - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
Small Molecule to Antagonize GPR20 for Gastro-Intestinal Stromal Tumors and Acute Myeloid Leukemia - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
TGR-1202 - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
vemurafenib - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
Gastrointestinal Stromal Tumor (GIST) - Recent Pipeline Updates 137
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 198
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 199
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 200
Featured News & Press Releases 200
Apr 20, 2016: Kolltan Pharmaceuticals Announces Presentations of Anti-KIT Antibody Preclinical Data at the 2016 American Association for Cancer Research Annual Meeting 200
Jul 13, 2015: Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for BLU-285 201
Apr 19, 2015: Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets 201
Apr 08, 2015: Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting 202
Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors 202
Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science's Masican 203
Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig 204
Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors 205
Jun 02, 2013: Threshold Pharma Announces Data From Two Ongoing Phase I/II Trials Of TH-302 At 2013 ASCO Annual Meeting 206
Apr 09, 2013: Ariad Pharma Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations In Oncogenic Driver Of Gastrointestinal Stromal Tumors 207
Appendix 208
Methodology 208
Coverage 208
Secondary Research 208
Primary Research 208
Expert Panel Validation 208
Contact Us 208
Disclaimer 209
List of Tables
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2016 11
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2016 21
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H1 2016 22
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories, LLC, H1 2016 23
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 24
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals, Inc., H1 2016 25
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc., H1 2016 26
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 27
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corporation, H1 2016 28
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical, Inc., H1 2016 29
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences, Inc., H1 2016 30
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2016 31
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 32
Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 33
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H1 2016 34
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H1 2016 35
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 36
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 37
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Limited, H1 2016 38
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences S.r.l., H1 2016 39
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1 2016 40
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corporation, H1 2016 41
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc., H1 2016 42
Gastrointestinal Stromal Tumor (GIST) - Pipeline by TG Therapeutics, Inc., H1 2016 43
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 44
Assessment by Monotherapy Products, H1 2016 45
Assessment by Combination Products, H1 2016 46
Number of Products by Stage and Target, H1 2016 48
Number of Products by Stage and Mechanism of Action, H1 2016 51
Number of Products by Stage and Route of Administration, H1 2016 54
Number of Products by Stage and Molecule Type, H1 2016 56
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Recent Pipeline Updates, H1 2016 137
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2016 198
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2016 199
List of Figures
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2016 11
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Products, H1 2016 18
Assessment by Monotherapy Products, H1 2016 45
Number of Products by Top 10 Targets, H1 2016 47
Number of Products by Stage and Top 10 Targets, H1 2016 47
Number of Products by Top 10 Mechanism of Actions, H1 2016 50
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 50
Number of Products by Routes of Administration, H1 2016 53
Number of Products by Stage and Routes of Administration, H1 2016 53
Number of Products by Molecule Types, H1 2016 55
Number of Products by Stage and Molecule Types, H1 2016 55
